Challenges in estimating waning effectiveness of two doses of BNT162b2 and ChAdOx1 COVID-19 vaccines beyond six months: an OpenSAFELY cohort study using linked electronic health records
Abstract Quantifying the waning effectiveness of second COVID-19 vaccination beyond six months and against the omicron variant is important for scheduling subsequent doses. With the approval of NHS England, we estimated effectiveness up to one year after second dose, but found that bias in such estimates may be substantial..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 06. Jan. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Horne, Elsie MF [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2023.01.04.22283762 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI03834470X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI03834470X | ||
| 003 | DE-627 | ||
| 005 | 20230429084059.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230106s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.01.04.22283762 |2 doi | |
| 035 | |a (DE-627)XBI03834470X | ||
| 035 | |a (biorXiv)10.1101/2023.01.04.22283762 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Horne, Elsie MF |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Challenges in estimating waning effectiveness of two doses of BNT162b2 and ChAdOx1 COVID-19 vaccines beyond six months: an OpenSAFELY cohort study using linked electronic health records |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Quantifying the waning effectiveness of second COVID-19 vaccination beyond six months and against the omicron variant is important for scheduling subsequent doses. With the approval of NHS England, we estimated effectiveness up to one year after second dose, but found that bias in such estimates may be substantial. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Hulme, William J |e verfasserin |4 aut | |
| 700 | 1 | |a Keogh, Ruth H |e verfasserin |4 aut | |
| 700 | 1 | |a Palmer, Tom M |e verfasserin |4 aut | |
| 700 | 1 | |a Williamson, Elizabeth J |e verfasserin |4 aut | |
| 700 | 1 | |a Parker, Edward PK |e verfasserin |4 aut | |
| 700 | 1 | |a Walker, Venexia M |e verfasserin |4 aut | |
| 700 | 1 | |a Knight, Rochelle |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Yinghui |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Kurt |e verfasserin |4 aut | |
| 700 | 1 | |a Fisher, Louis |e verfasserin |4 aut | |
| 700 | 1 | |a Morley, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Mehrkar, Amir |e verfasserin |4 aut | |
| 700 | 1 | |a Dillingham, Iain |e verfasserin |4 aut | |
| 700 | 1 | |a Bacon, Sebastien |e verfasserin |4 aut | |
| 700 | 1 | |a Goldacre, Ben |e verfasserin |4 aut | |
| 700 | 1 | |a Sterne, Jonathan AC |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 06. Jan. |
| 773 | 1 | 8 | |g year:2023 |g day:06 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.01.04.22283762 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 06 |c 01 | ||